Kyntra Bio halts FG-3246 prostate cancer trial, narrows focus to roxadustat
The company stopped its FG-3246/FG-3180 program after a Phase 2 interim look, restructured its royalty debt, and tied its Phase 3 roxadustat trial start to new financing or a partner.
SEC filing